Correlation of the EUROSCORE-II With POSPOM in Cardiac Surgery: A Single Center, Retrospective, Cross- Sectional Study
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Jan 8, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two scoring systems, EUROSCORE-II and POSPOM, to see how well they can predict the risk of death and complications after cardiac surgery. Cardiac surgery can be complex, especially for patients who may already have other health issues, so understanding a patient's condition before surgery is very important. The research is being conducted at Istanbul University-Cerrahpasa, Institute of Cardiology, and will involve patients who are 18 years or older and are undergoing specific types of heart surgeries, like coronary artery bypass grafting (CABG) or valve surgery.
If you or a family member are considering participating, you should know that the study is currently recruiting participants. Those involved will be monitored for any complications that might arise after surgery, such as bleeding, infections, or other serious issues. This trial aims to provide valuable information on how well these scoring systems work in predicting outcomes, which can help improve care for future cardiac surgery patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 and over, patients who have CABG surgery, valve surgery or both, and patients with on-pump surgery will be included in the study.
- Exclusion Criteria:
- • . Patients under the age of 18, patients with off-pump surgery, and patients with non-cardiac vascular surgery will be excluded from the study.
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Kerem Erkalp, Dr
Principal Investigator
Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported